Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?

Table 3 Clinical studies of second-line cytotoxic combination regimens

Ref.	Regimen	Sample size	RR1	PFS/TTP (mo)	Med OS (mo)	1 yr survival
	Platinum based regimens
Tsavaris et al[29], 2005	FOLFOX	30	23%	5.1	5.8	NR
Mitry et al[84], 2006	FOLFOX	18	0%	0.9	1.3	NR
Gebbia et al[85], 2007	FOLFOX	42	14%	4	6.7	NR
Novarino et al[86], 2009	FOLFOX	23	0%	2.7	4.0	NR
Yoo et al[30], 2009	FOLFOX	30	6.7%	1.4	3.5	NR
Chung et al[31], 2013	FOLFOX	44	11%	2.3	7.3	NR
Berk et al[35], 2012	FOLFOX	46	17%	3.7	5.8	NR
Sancho et al[32], 2008	CapOx2	18	5.6%	3.9	5.8	NR
Xiong et al[33], 2008	CapOx	41	2.4%	2.3	5.4	21%
Gasent-Blesa et al[34], 2009	CapOx	15	6.7%	NR	5.3	NR
Berk et al[35], 2012	CapOx	39	18%	3.7	4.9	NR
Pelzer et al[87], 2009	OFF	37	5.4%	2.8	5.1	NR
Pelzer et al[37], 2011	OFF	23	0%	NR	4.8	NR
Pelzer et al[38], 2008	OFF	76	NR	3	6.1	NR
Assaf et al[40], 2011	FOLFIRINOX	27	19%	5.4	8.5	NR
Togawa et al[88], 2007	Cisplatin, S-1	17	29%	NR	10	32%
Kim et al[89], 2012	Cisplatin, S-1	11	0%	1.5	2.7	NR
Takahara et al[90], 2013	Oxaliplatin, S-1	30	10%	3.4	5.0	NR
Cantore et al[41], 2004	Oxaliplatin, irinotecan	30	10%	4.1	5.9	23%
Oh et al[42], 2010	Oxaliplatin, irinotecan	14	21%	1.4	4.1	7.1%
Reni et al[43], 2006	Oxaliplatin, raltitrexed	41	24%	1.8	5.2	12%
Mazzer et al[44], 2009	Oxaliplatin, pemetrexed	16	56%	3.3	NR	NR
	Non-platinum based regimens
Yoo et al[30], 2009	FOLFIRI	31	0%	1.9	3.9	NR
Gebbia et al[45], 2010	FOLFIRI	40	15%	3.7	6.0	0%
Cereda et al[91], 2010	FOLFIRI or XELIRI	34	0%	2.0	4.2	5.6%
Zaniboni et al[46], 2012	FOLFIRI	50	8%	3.2	5.0	NR
Neuzillet et al[47], 2012	FOLFIRI	63	7.9%	3.0	6.6	NR
Mizuno et al[28], 2013	S-1, irinotecan	60	18%	3.6	6.9	NR
Blaya et al[49], 2007	Capecitabine, docetaxel	24	13%	NR	NR	NR
Katopodis et al[50], 2011	Capecitabine, docetaxel	31	9.7%	2.4	6.4	15%
Kim et al[51], 2009	5-FU, paclitaxel	28	10%	2.5	7.6	NR
Lee et al[92], 2009	Conti-FAM3	31	12%	2.3	6.7	NR
Shi et al[93], 2012	Capecitabine, thalidomide	31	6.5%	2.7	6.1	NR
Saif et al[94], 2009	Capecitabine, PHY906	25	5.3%	NR	NR	NR
Ulrich-Pur et al[48], 2003	Irinotecan, raltitrexed	19	16%	4.0	6.5	NR
Reni et al[95], 2004	MDI	15	0%	1.7	6.1	0%
Cereda et al[96], 2011	Mitomycin, ifosfamide	21	4.8%	1.7	3.7	9.5%
Ko et al[52], 2008	Irinotecan, docetaxel	14	0%	1.2	4.5	21%

¹Intent-to-treat analysis;

²Pooled analysis of pancreatic (50%), biliary (22%), gallbladder (22%) and ampullary (6%) cancer;

³Pooled analysis of pancreatic (48%), biliary (35%) and gallbladder (16%) cancer. FOLFOX: Oxaliplatin, 5-fluorouracil, folinic acid, biweekly; CapOx: Capecitabine, oxaliplatin; OFF: Oxaliplatin, 5-fluorouracil, leucovorin, in 6-wk cycles; FOLFIRINOX: Oxaliplatin, leucovorin, 5-fluorouracil, irinotecan; FOLFIRI: 5-Fluorouracil, leucovorin, irinotecan; XELIRI: Capecitabine, irinotecan; 5-FU: 5-Fluorouracil; Conti-FAM: 5-Fluorouracil, doxorubicin, mitomycin-c; MDI: Mitomycin, docetaxel, irinotecan; NR: Not reported; PFS: Progression free survival; OS: Overall survival; TTP: Time to progression.